Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
Statins291 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A00346 | 35126843 | World J Hepatol | Is there a role of lipid-lowering therapies in the management of fatty liver disease? | 2022 | Details |
| A00385 | 35107763 | Curr Atheroscler Rep | Childhood Hypertriglyceridemia: Is It Time for a New Approach? | 2022 | Details |
| A00546 | 35051605 | J Ethnopharmacol | Xiaoyao Powder in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis. | 2022 | Details |
| A00716 | 34992072 | BMJ Open Gastroenterol | Impact of statin treatment on non-invasive tests based predictions of fibrosis in a referral pathway for NAFLD. | 2022 | Details |
| A00759 | 34977520 | JHEP Rep | Real-world management of non-alcoholic steatohepatitis differs from clinical practice guideline recommendations and across regions. | 2021 | Details |
| A01020 | 34901236 | Front Cardiovasc Med | Statins in Non-alcoholic Steatohepatitis. | 2021 | Details |
| A01124 | 34862975 | FASEB J | Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling. | 2022 | Details |
| A01147 | 34855339 | FP Essent | Liver Disease: Nonalcoholic Fatty Liver Disease. | 2021 | Details |
| A01690 | 34653272 | Aliment Pharmacol Ther | Trends in statin utilisation in US adults with non-alcoholic fatty liver disease. | 2021 | Details |
| A01756 | 34628383 | Georgian Med News | THE INFLUENCE OF HYPERCHOLESTEROLEMIA AND CONCOMITANT STATIN THERAPY ON THE STATE OF PLATELET-PLASMA HEMOSTASIS IN PATIENTS WITH ESSENTIAL HYPERTENSION AND NON-ALCOHOLIC FATTY LIVER DISEASE. | 2021 | Details |
| A01809 | 34607067 | Clin Res Hepatol Gastroenterol | Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis. | 2021 | Details |
| A01931 | 34558856 | Hepatol Commun | Role of Cholesterol-Associated Steatohepatitis in the Development of NASH. | 2021 | Details |
| A02330 | 34416040 | Aliment Pharmacol Ther | Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. | 2021 | Details |
| A02532 | 34339764 | J Hepatol | Prevention of NAFLD-associated HCC: Role of lifestyle and chemoprevention. | 2021 | Details |
| A02922 | 34198964 | Antibiotics (Basel) | Nonalcoholic Fatty Liver Disease-A Novel Risk Factor for Recurrent Clostridioides difficile Infection. | 2021 | Details |
| A03095 | 34133035 | Br J Clin Pharmacol | Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis. | 2021 | Details |
| A03165 | 34106587 | Medicine (Baltimore) | Xuefu Zhuyu decoction for nonalcoholic fatty liver disease: A protocol for systematic review and meta-analysis. | 2021 | Details |
| A03334 | 34040322 | World J Gastroenterol | Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. | 2021 | Details |
| A03404 | 34014280 | Dis Model Mech | Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH. | 2021 | Details |
| A03593 | 33939118 | Drugs | Targeting AMPK by Statins: A Potential Therapeutic Approach. | 2021 | Details |
| A03831 | 33854987 | J Hepatocell Carcinoma | NAFLD-Associated HCC: Progress and Opportunities. | 2021 | Details |
| A03845 | 33849361 | Expert Opin Drug Discov | The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease. | 2021 | Details |
| A04052 | 33775894 | Clin Gastroenterol Hepatol | Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study. | 2021 | Details |
| A04204 | 33716004 | Metabolism | Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes. | 2021 | Details |
| A04349 | 33652942 | Int J Mol Sci | Treatments for NAFLD: State of Art. | 2021 | Details |
| A04462 | 33606428 | J Clin Gastroenterol | Effect of Statin Use on Cancer-related Mortality in Nonalcoholic Fatty Liver Disease: A Prospective United States Cohort Study. | 2022 | Details |
| A04659 | 33549441 | Nutr Metab Cardiovasc Dis | Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience. | 2020 | Details |
| A04908 | 33454241 | J Clin Lipidol | Interrogation of selected genes influencing serum LDL-Cholesterol levels in patients with well characterized NAFLD. | 2020 | Details |
| A05008 | 33413060 | Curr Med Chem | Lipid Metabolism and Relevant Disorders to Female Reproductive Health. | 2021 | Details |
| A05052 | 33392801 | Curr Atheroscler Rep | Selective Peroxisome Proliferator-Activated Receptor Alpha Modulators (SPPARMα) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel? | 2021 | Details |
| A05680 | 33162737 | Ann Gastroenterol | Nonalcoholic fatty liver disease and atrial fibrillation: possible pathophysiological links and therapeutic interventions. | 2020 | Details |
| A05712 | 33145423 | Clin Exp Hepatol | Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis - epidemiology, risk factors, clinical implications and treatment. | 2020 | Details |
| A05716 | 33144054 | Dig Liver Dis | Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. | 2020 | Details |
| A05931 | 33072455 | Cureus | Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. | 2020 | Details |
| A05967 | 33059580 | Curr Vasc Pharmacol | Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role? | 2021 | Details |
| A06054 | 33027082 | Am J Gastroenterol | Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study. | 2021 | Details |
| A06100 | 33007508 | Clin Gastroenterol Hepatol | Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease. | 2020 | Details |
| A06156 | 32984364 | Front Med (Lausanne) | Disturbances in Cholesterol Homeostasis and Non-alcoholic Fatty Liver Diseases. | 2020 | Details |
| A06637 | 32798709 | Clin Gastroenterol Hepatol | Effects of Metformin Exposure on Survival in a Large National Cohort of Patients With Diabetes and Cirrhosis. | 2020 | Details |
| A06900 | 32705195 | Mol Med Rep | Trimetazidine improves hepatic lipogenesis and steatosis in non‑alcoholic fatty liver disease via AMPK‑ChREBP pathway. | 2020 | Details |
| A06962 | 32685690 | Hepatoma Res | Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma. | 2020 | Details |
| A06984 | 32673798 | Mol Metab | Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. | 2020 | Details |
| A07066 | 32634622 | Clin Gastroenterol Hepatol | Real-World Burden of Nonalcoholic Steatohepatitis. | 2020 | Details |
| A07175 | 32592657 | Cell Metab | In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. | 2020 | Details |
| A07297 | 32552182 | Expert Opin Investig Drugs | Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). | 2020 | Details |
| A07591 | 32432142 | World J Clin Cases | Cholesteryl ester storage disease of clinical and genetic characterisation: A case report and review of literature. | 2020 | Details |
| A08115 | 32241197 | Expert Rev Gastroenterol Hepatol | Obeticholic acid for the treatment of nonalcoholic steatohepatitis. | 2020 | Details |
| A08373 | 32139507 | J Biol Chem | The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease. | 2020 | Details |
| A08447 | 32106257 | PLoS One | Serum miR-379 expression is related to the development and progression of hypercholesterolemia in non-alcoholic fatty liver disease. | 2020 | Details |
| A09047 | 31889754 | J Clin Exp Hepatol | Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A09079 | 31882668 | Sci Rep | Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH. | 2019 | Details |
| A09574 | 31690932 | J Clin Endocrinol Metab | Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. | 2020 | Details |
| A09609 | 31676775 | Sci Rep | Characterizing the Role of HMG-CoA Reductase in Aryl Hydrocarbon Receptor-Mediated Liver Injury in C57BL/6 Mice. | 2019 | Details |
| A09758 | 31622581 | Am J Med | Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction in Patients With Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A10018 | 31523440 | BMJ Open Gastroenterol | Real-world comorbidities and treatment patterns among patients with non-alcoholic fatty liver disease receiving phosphatidylcholine as adjunctive therapy in Russia. | 2019 | Details |
| A10238 | 31418344 | Curr Vasc Pharmacol | What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis? | 2019 | Details |
| A10276 | 31402538 | Liver Int | CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients. | 2019 | Details |
| A10502 | 31309820 | Curr Vasc Pharmacol | Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review. | 2019 | Details |
| A11179 | 31009793 | Clin Gastroenterol Hepatol | Risk Factors for Severe Liver Disease in Patients With Type 2 Diabetes. | 2019 | Details |
| A11267 | 30968536 | Liver Int | Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study. | 2019 | Details |
| A11279 | 30961499 | Curr Vasc Pharmacol | Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. | 2020 | Details |
| A11338 | 30931410 | Comput Toxicol | Frequent Modulation of the Sterol Regulatory Element Binding Protein (SREBP) by Chemical Exposure in the Livers of Rats. | 2019 | Details |
| A11476 | 30879942 | J Clin Lipidol | Extremely low levels of low-density lipoprotein potentially suggestive of familial hypobetalipoproteinemia: A separate phenotype of NAFLD? | 2019 | Details |
| A11488 | 30875495 | Atherosclerosis | Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes. | 2019 | Details |
| A11655 | 30802917 | Exp Clin Endocrinol Diabetes | Progression of Albuminuria Among Patients with Type 1 Diabetes Mellitus: A Long Term Observational Follow-up Study. | 2019 | Details |
| A11888 | 30694825 | Curr Opin Endocrinol Diabetes Obes | Dyslipidemia in nonalcoholic fatty liver disease. | 2019 | Details |
| A11998 | 30652643 | Curr Pharm Des | The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease. | 2018 | Details |
| A12298 | 30520543 | Cancer Sci | Ezetimibe suppresses development of liver tumors by inhibiting angiogenesis in mice fed a high-fat diet. | 2019 | Details |
| A12499 | 30420265 | Arab J Gastroenterol | Managing diabetes and liver disease association. | 2018 | Details |
| A12783 | 30288767 | Aliment Pharmacol Ther | Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany. | 2018 | Details |
| A12785 | 30288477 | Hepatol Commun | Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality. | 2018 | Details |
| A12865 | 30249980 | Diseases | Judicious Use of Lipid Lowering Agents in the Management of NAFLD. | 2018 | Details |
| A12912 | 30229482 | Hormones (Athens) | Lipids: a personal view of the past decade. | 2018 | Details |
| A12955 | 30210131 | Intern Med | Hepatitis B Virus Reactivation in a Patient with Nonalcoholic Steatohepatitis 41 Months after Rituximab-containing Chemotherapy. | 2018 | Details |
| A13196 | 30090738 | Indian J Endocrinol Metab | Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. | 2020 | Details |
| A13292 | 30047465 | Chin J Nat Med | Ilexgenin A enhances the effects of simvastatin on non-alcoholic fatty liver disease without changes in simvastatin pharmacokinetics. | 2018 | Details |
| A13371 | 30013416 | Clin Med Insights Gastroenterol | An Evidence-Based Review of Statin Use in Patients With Nonalcoholic Fatty Liver Disease. | 2018 | Details |
| A13598 | 29887885 | Adv Pharmacol Sci | Supplementation with Alpha-Tocopherol and Ascorbic Acid to Nonalcoholic Fatty Liver Disease's Statin Therapy in Men. | 2018 | Details |
| A14349 | 29452601 | Cardiovasc Diabetol | Reactive hyperemia index (RHI) and cognitive performance indexes are associated with histologic markers of liver disease in subjects with non-alcoholic fatty liver disease (NAFLD): a case control study. | 2018 | Details |
| A14388 | 29431526 | Expert Rev Gastroenterol Hepatol | The potential role of statins in treating liver disease. | 2018 | Details |
| A14423 | 29413998 | Curr Opin Pharmacol | Lipid-lowering treatment in peripheral artery disease. | 2018 | Details |
| A14576 | 29344336 | Ther Adv Endocrinol Metab | Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety. | 2017 | Details |
| A14791 | 29231919 | Pol Merkur Lekarski | [Non-alcoholic liver disease - diagnosis and treatment]. | 2017 | Details |
| A14824 | 29217477 | Biochim Biophys Acta Mol Cell Biol Lipids | Activation of hepatic Nogo-B receptor expression-A new anti-liver steatosis mechanism of statins. | 2017 | Details |
| A14850 | 29204050 | World J Gastroenterol | Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. | 2017 | Details |
| A15074 | 29108191 | Zhonghua Gan Zang Bing Za Zhi | [An interpretation of the AASLD practice guideline on the diagnosis and management of nonalcoholic fatty liver disease in 2017]. | 2017 | Details |
| A15279 | 28989095 | J Hepatol | Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. | 2017 | Details |
| A15357 | 28948002 | Oncotarget | Linking atrial fibrillation with non-alcoholic fatty liver disease: potential common therapeutic targets. | 2017 | Details |
| A15424 | 28919478 | Biochim Biophys Acta Mol Cell Biol Lipids | Atorvastatin reduces lipid accumulation in the liver by activating protein kinase A-mediated phosphorylation of perilipin 5. | 2017 | Details |
| A15544 | 28850969 | Dtsch Med Wochenschr | [Statins as a Therapy of Chronic Liver Disease?] | 2017 | Details |
| A15560 | 28843826 | Eur J Pharmacol | Zoledronic acid, an FPPS inhibitor, ameliorates liver steatosis through inhibiting hepatic de novo lipogenesis. | 2017 | Details |
| A15871 | 28676027 | Curr Vasc Pharmacol | The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options? | 2018 | Details |
| A15872 | 28676026 | Curr Vasc Pharmacol | A Critical Approach of Guideline Therapeutic Recommendations for NAFLD. | 2018 | Details |
| A15875 | 28676020 | Curr Vasc Pharmacol | Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease. | 2018 | Details |
| A15876 | 28676019 | Curr Vasc Pharmacol | Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. | 2018 | Details |
| A15877 | 28676018 | Curr Vasc Pharmacol | Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease? | 2018 | Details |
| A16092 | 28575232 | J Clin Endocrinol Metab | Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial. | 2017 | Details |
| A16175 | 28521870 | Metabolism | The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. | 2017 | Details |
| A16234 | 28494529 | Clin Mol Hepatol | NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs. | 2017 | Details |
| A16265 | 28479502 | Clin Gastroenterol Hepatol | Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta-analysis. | 2017 | Details |